The Centers for Disease Control and Prevention (CDC) has alerted the health care community of a “probable association” between myocarditis and some COVID-19 vaccines. In response, the Washington State Department of Health shared the document Information for Clinical Staff: Myocarditis and mRNA Vaccines (updated June 28) to help clinicians understand myocarditis and assist in discussing vaccine risks and benefits with patients. It includes talking points, guidance on responding to a patient who presents with myocarditis and other resources.
There has also been an update on antibody treatments for COVID-19. On June 25, the Assistant Secretary for Preparedness and Response (ASPR) and the FDA announced that ASPR was pausing distribution of bamlanivimab and etesevimab together and etesevimab alone. The FDA also recommends using alternative authorized monoclonal antibody therapies rather than bamlanivimab and etesevimab together. Additional details are available online.
